AstraZeneca

Open: 62.8 Close: 62.85 Change: 0.05

Stop waiting time to find out about AstraZeneca: Our AI summarizes all info about it.

Are looking for the most relevant information about AstraZeneca? Investor spend a lot of time searching for information to make investment decisions in AstraZeneca. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, vaccine, US, company, Astra, flu, Cambridge, and the most common words in the summary are: astrazeneca, vaccine, news, company, health, drug, astrazenecas, . One of the sentences in the summary was: Company asked FDA to allow intranasal flu vaccine to be administered at home.. Other …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

AstraZeneca PLC shares inched up 0.93% to £102.18 Monday. Company expects an FDA decision in the first quarter of 2024. Company asked FDA to allow intranasal flu vaccine to be administered at home.

Today's News

AstraZeneca PLC shares inched up 0.93% to £102.18 Monday, on what proved to be an all-around great trading session for the stock market. The company expects an FDA decision in the first quarter of 2024. AstraZeneca provides this link as a service to website visitors. AstraZecas global website is intended for people seeking information on Astra Zenecas worldwide business. AstraZeneca.com is the parent company of Astrazeneca PLC. The European Commission (EC) has approved Daiichi Sankyo and Astra. s antibody-drug conjugate ENHERTU (trastuzumab deruxtecan) to treat advanced non-small cell lung cancer (NSCLC) patients. AstraZeneca submitted application to FDA to allow intranasal flu vaccine to be administered at home by individuals or caregivers of healthcare professionals. FluMist Quadrivalent, the technology behind the nasal spray flu vaccine is not new. The US Food and Drug Administration is reviewing an application for the nasal spray flu vaccine FluMist to be able to be self-administered at home. AstraZeneca has asked the FDA to allow adults ages 18 to 49 to give themselves the vaccine, or to give it to children as young as 2. Patients would still need to go through an online pharmacy system to order the vaccine. AstraZeneca/Daiichi Sankyo datopotamab deruxtecan (Dato-DXd) reduced the risk of disease progression or death by 37% compared to chemotherapy, but the results did not reach statistical significance at the time of cut-off. GlobalData predicts that AstraZeal will lead the market. AstraZeneca (AZN, $61.92) RSI Indicator left the oversold zone on October 27, 2023 Tickeron - Stocks. This is a signal that AZNs price could be shifting from a downtrend to an uptrend. US Food and Drug Administration accepts for review AstraZenecas Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal). AstraZeneca announced eight winners of the 2023 R&D Postdoctoral Challenge and agreed to fund their postdoctoral positions at one of the Companys strategic R&Ds centres in either Cambridge, UK, Gaithersburg or Boston, US or Gothenburg, Sweden. AstraZeneca acquired US company MedImmune for about US$15.2 billion to gain flu vaccines and an anti-viral treatment for infants. Company announced plans for a major corporate restructuring. AstraZeneca has its corporate headquarters in Cambridge, United Kingdom, and main research and development (R&D) centres are in Cambridge (UK), Gaithersburg (Maryland, US), Gothenburg (Sweden) and Warsaw (Poland) Astra has a reputation in China that was tarnished following the 2008 Sichuan earthquake. AstraZeneca settled a lawsuit in the United States totalling US$68.5 million to be divided up to 38 states. Two years before omeprazole patent expired, Astra Zeneca patented S-omeprazole in pure form. AstraZeneca buys oncology-focused Spirogen for up to $440 million. AstraZeneca wins approval for Ovarian-Cancer Drug It Had Dropped Astrazeneca PLC was incorporated in 1992 and is headquartered in Cambridge, United Kingdom. The company was formerly known as the AstraZeneca Group and changed its name in April 1999.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

How much time have you spent trying to decide whether investing in AstraZeneca? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, vaccine, US, company, Astra, flu, Cambridge, and the most common words in the summary are: astrazeneca, vaccine, news, company, health, drug, astrazenecas, . One of the sentences in the summary was: Company asked FDA to allow intranasal flu vaccine to be administered at home.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #vaccine #news #company #health #drug #astrazenecas.